Kornimate/medical-research-clean huggingface dataset:
a search for helicobacter pylori in localized vulvodynia

Conditions: Vulvodynia; Vulvar Vestibulitis

Summary: hypothesis: to examine a possible association between localized vulvodynia and h. pylori infection.

subsequent sections from the paraffin blocks were prepared and stained by modified giemsa. immunostaining for h. pylori was done as described. in short, tissue sections were deparaffinized in xylene, rehydrated through decreasing concentrations of alcohol ending in phosphate-buffered saline (pbs), and subjected to pretreatment with proteinase k (8 minutes). the sections were quenched with 3% hydrogen peroxidase, incubated with protein block for 15 minutes at room temperature, and washed in pbs. tissues then were incubated with polyclonal rabbit anti-h pylori antibody (dilution, 1:10; clone ch-20 429, dako, carpinteria, ca). finally, sections were washed in 0.05% polysorbate 20 in pbs, ph 7.4, and the bound antibody was detected using streptavidin and biotinylated secondary antibody with diaminobenzidine as the chromogen. sections were counterstained with hematoxylin, dehydrated, and mounted. negative controls were sections treated as above, but instead of incubation with the primary antibody, they were incubated with 1% bovine serum albumin in pbs. vulvar biopsies of seven other women without localized vulvodynia served as healthy controls. the positive and negative control gastric tissues for the immunohistochemical stain of the h. pylori microorganisms were obtained from the archives of the department of pathology.

Eligibility criteria:
inclusion criteria: * paraffin blocks of vestibular tissues from patients with vestibulodynia exclusion criteria: * patients without vestibulodynia

Keywords: localized vulvodynia helicobacter pylori peptic disease omeprazole
predictors of outcome in patients with pleural infection at sohag university hospital

Conditions: Pleural Infection

Summary: pleural infection remains a common medical problem with significant mortality and morbidity despite a better undrstanding of the aetiology , pathophysiology and recent advances in management approaches . the cornerstones of the managment op pleural infection include early identification of cases and accurate diagnosis . suitable antibiotic therapy , nutrition managment , efficient drainage of infected collection via chest tube with or without adjunctive therapies including intrapleural agents and ultimately surgical managment .


Eligibility criteria:
inclusion criteria: * patients more than 18 years old with pleural infection exclusion criteria: * hemothorax * chest trauma within 3 month * underwent thoracic surgery within 60 days
the effect of controlled feedback on the rehabilitation of individuals with disability due to stiff shoulder following trauma

Conditions: Fracture Humerus

Summary: this study will compare the effect of manipulated vs. non-manipulated feedback during the rehabilitation of individuals with disability due to stiff shoulder following multiple trauma. this will be accomplished using the state-of-the-art real-time motion capture technology.

in this intervention, comparative study, 30 individuals with stiff shoulder following fracture to the proximal humerus (4 weeks to 6 months following the injury) will be treated at the gait and motion laboratory at the hadassah medical center in jerusalem. each subject will undergo a 12-session treatment (2-3 times a week, 30 minutes per session). in each session, reflective markers will be placed on the upper or lower body of the patient. ten fast infra-red cameras will detect the movement of the patient and provide real-time feedback when obtaining a correct movement pattern, as instructed by the therapist, pretrial. the motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. this could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist. the subjects will be randomly divided into two groups. one group will receive the non-manipulated feedback treatment for 6 sessions and then the manipulated feedback treatment for the remaining 6 sessions and vice versa for the second group. the shoulder passive and active range of motions, pain and activity levels will be tested 3 times: at baseline, following 6 and 12 sessions. a satisfactory questionnaire will be filled out by each patient twice, following 6 and 12 sessions. the study will test for no differences in the overall progress of the patients during the 12-session rehabilitation period. the study will further test for differences in all outcome measures between the manipulated and non-manipulated treatment sessions.

Eligibility criteria:
inclusion criteria: * restricted shoulder motion (up to 90 degrees in abduction and flexion) following proximal humerus fracture, 4 weeks to 6 months following injury, without rotatory cuff tear * normal or corrected eyesight and hearing. exclusion criteria: * neurological deficiencies that restrict upper limb. * previous injury to the shoulder
clinical validation of breath analyser tests for diagnosis of covid-19.

Conditions: COVID-19

Summary: the sponsor has developed a rapid screening tool intended to determine if the subject tested is covid-19-free (negative to covid-19).

within this proposed project, the nhs will collect two diagnostic or screening tests per participant. one sample will be used by nhs and be run through regular diagnostics. the second, will be breath sample which will be tested using the biosafety technologies ltd, rapid screening tool. this will use a pre-defined protocol. these tests would then be compared to assess the diagnostic efficacy including sensitivity and specificities. we will be aiming to achieve a significant comparison to ensure certainty and to exploit the information for proposing a novel diagnostic system to enhance capabilities to scale up the testing of patients. the proposed activity involves clinical validation of biosafety testing, to enhance the performance of detection along with clinicians.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * requiring a diagnostic or screening rt-pcr test for covid-19 exclusion criteria: * subjects under general anaesthesia * the inability to personally sign the consent form. * the inability to exhale breath
safety and efficacy study of peginterferon lambda-1a vs. peginterferon alfa-2a, plus ribavirin in subjects with genotype 1 hepatitis c

Conditions: Hepatitis C Virus (HCV)

Summary: the purpose of this study is to determine if 48 weeks of therapy with peginterferon lambda plus ribavirin is effective and safe for a treatment of chronic hepatitis c (chc) compared to therapy with peginterferon alfa-2a plus ribavirin.


Eligibility criteria:
inclusion criteria: * chronic hepatitis c, genotype 1 * hcv rna ≥100,000 iu/ml at screening * liver biopsy documenting no cirrhosis (within prior 3 years). where approved for staging of liver disease, non-invasive imaging may be used to assess the extent of liver disease * naïve to prior anti-hcv therapy exclusion criteria: * infected with hcv other than genotype 1 * positive hepatitis b surface antigen (hbsag), or human immunodeficiency virus (hiv)-1/hiv-2 antibody at screening * evidence of liver disease other than hcv * active substance abuse * use of hematologic growth factors within 90 days prior to study randomization * evidence of history of cirrhosis based on radiologic criteria or biopsy results and clinical criteria
the effect of education on patient compliance

Conditions: Glaucoma

Summary: with patient education, the compliance with glaucoma medications will increase.

we divided glaucoma patients into two groups; one watched a video the others did not. we checked their intraocular pressures before and after the intervention to see if there was a difference

Eligibility criteria:
inclusion criteria: * glaucoma patients coming in for routine examination exclusion criteria: * if glaucoma was unstable and treatment regimen required a change

Keywords: glaucoma compliance intraocular pressure video
high intensity lipid lowering following acute coronary syndromes for persons living with hiv

Conditions: HIV Infection; Coronary Heart Disease

Summary: hillclimber is a randomized, controlled, open-label phase ii trial of moderate dose statin therapy (pravastatin 40mg daily) versus high-dose statin therapy (rosuvastatin 20-40mg daily) in hiv-infected persons taking antiretroviral therapy (art) who have coronary heart disease (chd).

hillclimber is a randomized, controlled, open-label phase ii trial of moderate dose statin therapy versus high-dose statin therapy in hiv-infected persons taking antiretroviral therapy (art) who have coronary heart disease (chd). all subjects will have an initial 2-week run-in period with pravastatin 40mg daily (week 0 to 2). subjects not demonstrating significant toxicity at week 2 will then be randomized to rosuvastatin 20mg (high intensity dose group) versus continuing pravastatin 40mg daily (moderate intensity group) for 12 weeks (weeks 2 to 14). at week 6, those in the rosuvastatin arm who do not demonstrate significant toxicity and whose ldl-c is \>60mg/dl and decreased by less than 25% compared with week 2 will then have doses increased to rosuvastatin 40mg.

Eligibility criteria:
inclusion criteria: * hiv-1 infection * hiv rna below the lower limit of assay detection within 12 months of study entry * 1) documented coronary heart disease (chd): nonfatal mi, unrecognized mi, unstable angina pectoris, and/or stable angina pectoris, as defined by the american heart association case definitions for acute coronary heart disease in epidemiology and clinical research studies, or or (2) documented 10-year ascvd risk of 15% or greater based on the acc/aha ascvd risk estimator * negative serum or urine pregnancy test * men and women age 18 to 75 years of age exclusion criteria: * serious illness or aids-related complication within 21 days of screening requiring systemic treatment and/or hospitalization * no coronary heart disease (chd) and 10-year ascvd risk \<15.0%. * not currently receiving antiretroviral therapy or taking any of the following antiretroviral agents: atazanavir/ritonavir, lopinavir/ritonavir. * history of statin intolerance leading to discontinuation, dose decrease, or change to less potent dose equivalent * statin absolute contraindication * current use of atorvastatin 20mg daily or greater or rosuvastatin 10mg daily or greater * chronic kidney disease stage 4 or greater (including dialysis) * systolic heart failure with last documented lvef \<35% * pregnant or breastfeeding * laboratory values obtained within 45 days prior to study entry: ldl-c \ 3 x upper limit of normal (uln) ast \> 3 x uln creatinine kinase (ck) \>3 x uln (calculated creatinine clearance (crcl) \<50 ml/min, as estimated by the cockcroft-gault equation) * life expectancy \<12 months * prior organ transplant * active malignancy * inflammatory muscle disease
satiety and alcohol challenge

Conditions: Alcohol Drinking

Summary: the goal of this pilot study is to identify the role of satiety on responses to alcohol drinking using human subject laboratory methods. satiety will be manipulated over two sessions using a dietary supplement (fiber+green tea) or a calorically matched placebo. responses to an acute alcohol challenge are measured.

participants will receive a beverage containing either a dietary supplement (10g fibersol®-2 mixed with water and aspartame sweetener for taste + 725mg decaffeinated green tea extract capsule) or a calorically matched placebo supplement (aspartame sweetener mixed with water + aspartame capsule) counterbalanced at two separate visits. forty-five minutes after the dietary supplement, a priming drink (calculated to achieve 30mg% blood alcohol concentration; bac) is administered. response to alcohol is measured using standardized questionnaires and a cognitive task. then over a 2-hour period, additional mini-drinks are administered. responses to standardized questionnaires are collected after each drink.

Eligibility criteria:
inclusion criteria: * age 21-45 * meeting niaaa criteria for current at-risk drinking (i.e., \>7/14 drinks in one week for women/men, with at least one episodes of 4+/5+ drinks in the past 30 days) * willingness to complete laboratory sessions involving blood draws and alcohol administration * ability to communicate and read in english * body mass index (bmi) of 21 - 30 kg/m\^2 exclusion criteria: * meets past-year criteria for severe alcohol use disorder (\>7 of 11 symptoms endorsed) or audit score of 20+ * meeting past-year criteria for a substance use disorder (with the exception of alcohol, tobacco or mild cannabis use disorder) * current engagement in alcohol treatments, or currently engaged in intentional efforts to quit alcohol use * current use of weight control medications * lifetime diagnosis of severe mental illness (including schizophrenia and bipolar disorder) * history of suicide attempt, or psychiatric hospitalization in the last 6 months * history of diabetes * medical conditions or medications for which alcohol is contraindicated * pregnant, nursing, or trying to become pregnant * plans to travel during the duration of study participation
effects of dry needling on the behavior of the shoulder muscles

Conditions: Shoulder Pain

Summary: the main objective of this study will be to evaluate the effects of the application of the dry needling technique on the activity of the rotator cuff muscles in the shoulder. the evaluation of the effects of the application of the dry needling technique will be carried out in subjects with and without shoulder pain.to do this, muscle strength, possible thickness changes in the muscle and electromyographic activity will be measured before and immediately after the application of a dry needling technique. likewise, other variables will be measured such as the pressure pain threshold (ppt), pain with a numeric verbal scale, kinesiophobia and catastrophism, the shoulder pain and disability index (spadi) and the influence of expectations about dry needling.


Eligibility criteria:
inclusion criteria: * subjects of legal age * subjects without shoulder pain or with unilateral shoulder pain of \> 3 months duration. * have shoulder mobility of 90º of abduction and at least 30º of glenohumeral external rotation. exclusion criteria: * have neck pain. * whiplash * having had trauma to the shoulder. * having fibromyalgia. * be pregnant. * being afraid of needles.

Keywords: dry needling shoulder muscle strength surface electromyography
the effect of aromatherapy massage on pain, anxiety and comfort

Conditions: Respiratory Insufficiency; Pulmonary Disease, Chronic Obstructive; Diabetes Mellitus, Type 2; High Blood Pressure; Stroke, Ischemic

Summary: patients in the intensive care unit (icu) experience physical and psychological discomfort, including pain. anxiety is a condition frequently encountered in the icu. the hospital environment, especially the icu, is reported as a significant cause of anxiety for patients. comfort is a holistic, subjective and multidimensional concept that is affected by physical, environmental, social and psycho-spiritual contexts and changes over time and space. comfort in intensive care is often associated with pain relief and end-of-life care. assessment tools have been developed to measure patient comfort in the icu, including levels of pain, delirium, and sedation. this work; patients who are monitored in intensive care under high-flow and oxygen are treated with a mixture of lavender, thyme and eucalyptus oil (20 ml; lavender oil 5 drops, thyme oil 4 drops, eucalyptus oil 3 drops and 20 ml almond oil) twice a day for three days. this study was conducted to determine the effect of aromatherapy massage applied for a total of 30 minutes on some physiological parameters, pain, anxiety and intensive care comfort of the patients.


Eligibility criteria:
inclusion criteria: * 18 years of age and over, * conscious patients, * staying in intensive care for 24 hours or more, * those with stable hemodynamic status, * receiving o2 therapy, * intubated patients, patients who have passed 24 hours after being extubated, * those whose saturation level is 85 and above exclusion criteria: * patients with peripheral neuropathy or quadriplegia, * patients with open wounds on their body, * patients receiving analgesia and sedation infusion, * patients who are sedated, * patients in delirium, * patients with an allergy detected before starting the application, * patients with a gks (glasgow coma scale) score of 3 and below

Keywords: intensive care pain anxiety comfort aromatherapy massage
the effects of a ruminococcus torques strain bacterium in healthy adults.

Conditions: Overweight; Healthy

Summary: a randomized, placebo controlled crossover study investigating the potential metabolic effects of the naturally occurring gut microbe ruminococcus torques in healthy, overweight adults.

by analyzing blood samples, indirect calorimetric as well as thermographic assessment of clavicular temperature we want to investigate whether or not the commensal gut bacterium ruminococcus toqrues strain atcc 27756 has any metabolic effects in healthy adults. the subjects will recieve the intervention with the live bacterium given through a duodenal feeding tube. the trial is double blinded and placebo controlled using a crossover design. subjects will be given an intervention with either placebo or ruminococcus on two different study days with up to six weeks of wash-out between each study day.

Eligibility criteria:
inclusion criteria: * age between 18 and 40 years * self-reported good health * caucasian * body mass index \> 27 kg/m\^2 exclusion criteria: * any known disorder/disease that could interfere with study results or is seen as compromising to the study (as assessed by the investigator), for example diabetes, cancer or cardiovascular or kidney disease. * use of any daily medication as well as p.r.n. (pro re nata; not taken regularly) medication that cannot be discontinued during the trial * use of antibiotics during the recent three months * acute or chronic gastrointestinal symptoms * lactose intolerance * pregnancy - ongoing or planned * smoking * alcohol or drug abuse * use of creatine as dietary supplement during study period * plasma creatinine above the normal range (\>105 μmol/l for men and \>90 μmol/l for women) * known significant liver disease or plasma alanine transaminase concentration ≥ 3 × normal value * values for hemoglobin, leukocytes, or thrombocytes outside of the normal ranges

Keywords: metabolism microbiota ruminococcus torques
pilot trial of adaptive radiotherapy boost for hnscc

Conditions: Squamous Cell Carcinoma; Head and Neck Cancer

Summary: the purpose of the study is to determine if it is feasible to use magnetic resonance imaging (mri) to adjust a portion of radiation therapy for patients with head and neck squamous cell carcinoma . the technique under study will be used to personalize the study treatment based on response, keeping all treatments within standard of care guidelines.


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * ecog performance status of 0, 1 * patients with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or unknown primary in the neck. * patients with measurable disease, either at primary site or neck per recist 1.1. * for patients planned to receive chemotherapy, adequate hematologic, hepatic and renal function as outlined in protocol. * international normalized ratio of prothrombin time (inr) and prothrombin time (pt) within 28 days before randomization must be wnl for the lab. patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history. * negative serum pregnancy test within before starting study treatment in woman with childbearing potential. exclusion criteria: * pregnancy or lactation * patients who have had prior radiotherapy to the head and neck or prior systemic therapy for the index cancer. * patients who had undergone definitive surgery for the index cancer. * patients with distant metastatic disease * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
does tdcs is effective in the prophylactic treatment of migraine

Conditions: Migraine

Summary: migraine has been described as one of the most common neurological diseases, with high social and economic impact. despite the high prevalence, the pathophysiology of migraine is still unknown, several studies have been developed in order to advance the understanding of the pathophysiological mechanisms of the disease which are not yet entirely elucidated. the aim of this study is to observe the effects of transcranial direct current stimulation (tdcs), applied in the visual cortex, on neurophysiological and clinical measures (frequency, intensity, duration of attacks and severity of pain) in migraine patients.


Eligibility criteria:
inclusion criteria for migraine patients: * age must be between 18 to 40 years * gender: male and female * diagnosis must meet the 2004 ihs criteria for migraine without aura and migraine with aura * duration of the disease must be at least 12 months * patients had no preventative medication consistently for at least six months prior to study initiation. inclusion criteria for healthy individuals * age must be between 18 to 40 years * gender: male and female * individuals who have not filed headache crisis in the last year assessed according to the 2004 ihs criteria exclusion criteria * pregnant woman * individuals with clinical evidence of brain injury * metallic implant head * pacemaker * history of seizure and chronic pain associated with other pathologies

Keywords: eeg migraine pain phosphene tdcs tms
myocet, docetaxel & trastuzumab as 1st line treatment of patients with her-2/neu positive metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: to study the pharmacokinetic profile of the therapeutic schedule in order to demonstrate absence of negative interactions among the 3 drugs administered

1. to assess the maximum tolerated dose (mtd) of myocet at different dosages in combination with taxotere at the fixed dose of 35 mg/m2 on day 2 and 9 every 21 days and weekly herceptin as first line therapy in patients affected by her-2/neu positive metastatic breast cancer 2. to enhance the proportion of complete remission 3. to allow the feasibility of the combination of herceptin with both myocet and taxotere without an enhanced risk of cardiotoxicity

Eligibility criteria:
inclusion criteria: * her-2/neu overexpression assessed by fish test or with immunohistochemical methods: dako(the result must be 3+ with dakotest); if the immunohistochemical test results 2+ it is needed a positive fish test * female \< 70yrs * histologically or cytologically proven breast cancer. * metastatic or locally advanced breast cancer (clinical stage: iii-iv) * adequate hematological, hepatic, renal and cardiac function, the latter confirmed by echocardiography with fevs ≥50% * prior adjuvant chemotherapy if doxorubicin total dose ≤300 mg/m2, epirubicin total dose ≤450 mg/m2 exclusion criteria: * history of cardiopathy * severe hepatic and renal diseases * brain metastases as the only parameter of disease * contraindication to the use of corticosteroids as premedication * acute infectious diseases * insulin-dependent diabetes * history of other cancers except for adequately treated basal cell skin cancer or in situ carcinoma of the cervix * concurrent treatment with any other cancer therapy